Every Form 4 that Strata Critical Medical, Inc. (SRTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SRTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRTA filings page.
Strata Critical Medical, Inc. Co-CEO and General Counsel Melissa M. Tomkiel acquired 177,858 Class A common shares on September 24, 2026, after the Compensation Committee certified that performance criteria for her performance-based restricted stock units were satisfied; the units were granted on August 29, 2026. On September 24, the issuer withheld 90,797 shares at $5.27 per share to satisfy tax withholding obligations related to PSU vesting.
Strata Critical Medical, Inc. (SRTA) Co-CEO and CFO William A. Heyburn acquired 177,858 shares of Class A common stock on September 24, 2026, after the Compensation Committee certified that performance criteria for performance-based restricted stock units granted August 29, 2025, had been satisfied. On that date, the issuer withheld 98,356 shares at a reported $5.27 per share to satisfy tax withholding obligations related to PSU vesting.
Strata Critical Medical, Inc. (SRTA) reported that officer Louis R. Verdetto, CEO, Clinical Services, had 5,697 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations related to vesting restricted stock units at $5.31 per share. After this withholding, he holds 1,128,096 shares directly and 132,232 shares indirectly through the LOUIS VERDETTO IRREVOCABLE TRUST DATED AUGUST 20 2025. No Rule 10b5-1 trading plan is reported.
Strata Critical Medical, Inc. (SRTA) reported that officer Scott M. Wunsch, CEO, Logistics, had 5,711 shares of Class A common stock withheld on September 8, 2026 to pay tax liabilities tied to vesting restricted stock units, at a reference value of $5.31 per share; no Rule 10b5-1 plan is reported. After this tax-withholding disposition, he holds 663,043 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. (SRTA) reported that Chief Accounting Officer Amir Cohen had 4,645 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations related to vesting restricted stock units. The shares were valued at $5.31 per share for this purpose, and Cohen now holds 177,154 shares directly.
Strata Critical Medical, Inc. (SRTA) reported that Co-CEO and General Counsel Melissa M. Tomkiel had 29,730 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. This tax-withholding disposition left her holding 2,066,617 shares directly. No Rule 10b5-1 trading plan is reported for this transaction.
Strata Critical Medical, Inc. (SRTA) reported that Co-CEO and CFO William A. Heyburn had 31,671 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This was a share withholding, not an open-market sale, and Heyburn now directly holds 1,678,348 shares of Class A common stock.
Strata Critical Medical, Inc. director Reginald Love reported a sale of 5,091 shares of Class A common stock on August 10, 2026 at $5.75 per share in an open market or private transaction. Following this sale, he directly holds 146,481 shares of the company’s common stock.
Cook William L. III reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director William L. Cook III received a grant of 44,438 Restricted Stock Units (RSUs) on July 30, 2026. The RSUs, granted at $0.0000 per share, will settle in Class A common stock when vested, with 100% vesting on the date of the company’s 2027 Annual Meeting of Stockholders. Following this award, Cook directly holds 97,671 shares of Class A common stock.
Love Reginald reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Reginald Love received a grant of 37,675 Restricted Stock Units (RSUs) on July 30, 2026. The RSUs will be settled in Class A common stock and 100% vest on the date of the company's 2027 Annual Meeting of Stockholders. Following this equity award, Love's reported direct holdings total 151,572 shares of Class A common stock.
PHILIP EDWARD M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. director Philip Edward M received a grant of 30,913 shares of Class A common stock on July 30, 2026, in the form of Restricted Stock Units. The RSUs will be settled in common shares and 100% vest on the date of the company’s 2027 Annual Meeting of Stockholders. Following this equity award, he holds 265,078 shares directly.
WIESENTHAL ROBERT S reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Robert S. Wiesenthal received a grant of 50,234 Restricted Stock Units (RSUs) of Class A common stock on 2026-07-30. These RSUs will be settled in shares upon vesting, with 100% vesting on the date of the company’s 2027 Annual Meeting of Stockholders. Following this award, Wiesenthal holds 5,325,896 shares of Class A common stock. The award carries a stated price of $0.0000 per share, reflecting a non-cash equity grant.
LAUCK ANDREW reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Andrew Lauck received a grant of 35,260 Restricted Stock Units (RSUs) on 2026-07-30, which will settle in Class A common shares upon vesting. All RSUs vest on the date of the 2027 Annual Meeting of Stockholders. Following this award, Lauck's reported direct holdings are 170,902 shares.
Strata Critical Medical, Inc. reported that CEO, Logistics Scott M. Wunsch acquired 57,172 shares of Class A common stock on July 30, 2026 at no cost upon certification that performance criteria under previously granted PSUs were satisfied. On July 31, 2026, 13,992 shares were withheld at $5.09 per share to satisfy related tax obligations. In addition, 382,987 shares of Class A common stock are held indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical Co-CEO and CFO William A. Heyburn reported PSU-related equity activity. On July 30, 2026, he acquired 181,071 and 179,160 Class A common shares at no cost upon certification of performance-based RSU criteria. On July 31, 199,209 shares were withheld at about $5.09 per share to satisfy tax withholding obligations tied to this PSU vesting.
Strata Critical Medical director and co-CEO Melissa M. Tomkiel reported equity compensation changes in Class A common stock. On July 30, 2026 she acquired 208,929 and 206,953 shares upon vesting of performance-based restricted stock units from March 8, 2024 and March 20, 2025 grants. On July 31, 2026 the issuer withheld 212,309 shares at $5.09 per share to satisfy tax withholding obligations related to the PSU vesting.
On July 30, 2026, Cohen Amir, Chief Accounting Officer of Strata Critical Medical, Inc., received 41,786 and 27,420 shares of Class A common stock upon certification that performance goals were met on earlier performance-based restricted stock unit (PSU) awards. On July 31, 2026, 34,015 shares were withheld at $5.0900 per share to satisfy related tax withholding obligations.
Strata Critical Medical, Inc. director and Co-CEO/CFO William A. Heyburn amended a prior insider filing to correctly classify a June 8, 2026 transaction as a tax-withholding event rather than a sale. On that date, 31,671 shares of Class A common stock at $5.87 per share were withheld by the company to cover tax obligations tied to the vesting of restricted stock units, in a transaction approved under Rule 16b-3. After this withholding, Heyburn directly held 1,548,997 shares of Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported a routine tax-related share disposition. On June 8, 2026, 4,655 shares of Class A common stock were withheld by the company at $5.87 per share to cover tax obligations from vested restricted stock units, leaving 146,608 shares owned directly. This amended Form 4 corrects an earlier filing that had mistakenly classified the event as an open-market sale, clarifying it was a tax-withholding transaction approved under Rule 16b-3.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported that 29,730 shares of Class A common stock were withheld by the company at $5.87 per share to cover tax obligations from a restricted stock unit vesting. This Form 4/A corrects a prior filing that had mistakenly used a sale code instead of the proper tax-withholding code, while confirming all other details were unchanged. After this tax withholding, she directly holds 1,892,774 shares.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch filed an amended insider report to correct how a prior share disposition was coded. On June 8, 2026, 5,550 shares of Class A common stock were withheld by the company at $5.87 per share to cover tax obligations from a restricted stock unit vesting, a non-market transaction approved under Rule 16b-3.
The earlier Form 4 had incorrectly used a sale code; this amendment changes it to the proper tax-withholding code F, with all other information unchanged. After the transaction, Wunsch directly holds 625,574 shares, with an additional 382,987 shares held indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported a Form 4 transaction involving company Class A common stock. On June 8, 2026, 31,671 shares were surrendered at a price of $5.87 per share. According to the footnote, these shares were withheld by the company to cover tax withholding obligations tied to the vesting of restricted stock units, rather than sold in the open market. After this tax-related share withholding, Heyburn held 1,548,997 shares directly, indicating he retained a substantially larger equity position in the company.
Strata Critical Medical, Inc. Chief Accounting Officer Cohen Amir reported an open-market sale of Class A common stock. On June 8, 2026, he sold 4,655 shares at $5.87 per share. After this transaction, he directly holds 146,608 shares of the company’s common stock.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. CEO of Logistics Scott M. Wunsch reported an open-market sale of 5,550 shares of Class A common stock at $5.87 per share. After this sale, he holds 625,574 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported open-market sales of company Class A common stock. On May 22, 2026, he sold 40,575 shares at a weighted average price of $5.91 per share. On May 21, 2026, he sold an additional 10,300 shares at a weighted average price of $5.79 per share. After these transactions, Cohen directly held 151,263 shares of Class A common stock. The filing notes that at least one of the transactions was executed under a pre-arranged Rule 10b5-1 trading plan, indicating the sales were scheduled in advance.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. reported that Velibor Krstic, a ten percent owner, had 1,577,500 warrants to purchase Class A Common Stock expire. These warrants, exercisable at $11.50 per share, expired worthless on May 7, 2026 under a Warrant Agreement dated September 12, 2019. Following the expiration, no warrants of this series remain held by the reporting person.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch reported equity compensation activity involving Class A common stock. On April 23, 2026, he acquired 57,172 shares at $0.0000 per share as a grant tied to performance-based restricted stock units that vested after meeting certified performance criteria.
On April 24, 2026, the company withheld 13,922 shares at $4.92 per share to cover tax obligations related to the PSU vesting, a non-market disposition. Following these transactions, he held 631,124 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported equity compensation activity involving the company’s Class A common stock. On April 23, 2026, he acquired 545,625 shares at $0.0000 per share upon vesting of performance-based restricted stock units granted on March 20, 2025, after the compensation committee certified that performance criteria were met.
On April 24, 2026, 301,731 shares were disposed of at $4.92 per share through shares withheld by the issuer to cover tax withholding obligations related to the PSU vesting, rather than an open-market sale. Following these transactions, Heyburn directly held 1,580,668 shares of Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Cohen Amir reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen received an equity award in the form of 64,191 Restricted Stock Units (RSUs) of Class A common stock, reported at a price of $0.00 per share. After this grant, his directly held stake increased to 181,817 shares.
The RSUs will be settled in common shares as they vest. According to the vesting schedule, 6.25% of the RSUs (rounded down to the nearest whole number) will vest every three months after March 8, 2026, with any remaining unvested RSUs vesting on March 8, 2030, as long as he continues serving the company.